Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344379 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2PIM3PIM2TERTPOLB | |
| SCHEMBL2723759 | 0.77 | LCK (0.41) | KDM4ETERTPOLB | |
| SCHEMBL3840072 | 0.74 | KDM4C (0.37) | — | |
| SCHEMBL2481184 | 0.73 | CHRM4 (0.31) | — | |
| SCHEMBL3342406 | 0.72 | ELANE (0.40) | PIM3PIM2KDM4E | |
| SCHEMBL2931203 | 0.72 | KDM4E (0.38) | PIM3PIM2KDM4E | |
| SCHEMBL3347796 | 0.72 | POLB (0.33) | SMN1; SMN2PIM3PIM2KDM4ETERT | |
| SCHEMBL15516056 | 0.71 | — | — | |
| SCHEMBL22265119 | 0.69 | ADORA3 (0.35) | — | |
| SCHEMBL15516368 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | SMN1; SMN2 2596/4885PIM3 3973/4885PIM2 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.